Eight months into the NHS's mass rollout of weight-loss injections, the health system in England is still finding its footing: some family doctors have not yet begun prescribing, and the government has answered with a £25 million incentive. It is a familiar human tension, the wish to offer a new remedy fairly to everyone who needs it, set against the practical limits of the clinicians who must deliver it. Whether money can bridge that distance between a promise made at the top and the consulting room where it is kept remains an open question.
GPs to Be Offered Financial Incentives to Prescribe Weight-Loss Drugs as NHS Access Gaps Persist
Access should be based on need, not ability to pay.
Mark
Eight months in, and some GPs still aren't prescribing. Why is that the headline?
Mimi
Because the rollout depends on them. The government has now confirmed that not all practices prescribe, so where you live may shape whether you get the drug.
Mark
And the answer is £25 million in incentives?
Mimi
Yes, tied to prescribing and to referring eligible patients to weight management services, within the new GP contract.
Luke
Worth noting the source doesn't say how many practices are holding out. We know the gap exists, not how big it is.
Mark
Why would GPs hold back?
Mimi
Workload was the concern raised at launch. NHS England's own modelling said that if 70 per cent of over three million eligible patients started treatment in year one, it would take 18 per cent of GP appointments.
Luke
That's a scenario, though, not a forecast of what is happening. And the source doesn't say workload is the reason any given practice isn't prescribing.
Mark
What about the private market?
Mimi
About 2.4 million people take these drugs, mostly privately. Research this month suggests women and the middle classes dominate private prescriptions.
Luke
The 2.4 million is an estimate, and the reporting doesn't say who produced it. Likewise, we don't know yet if the money will change prescribing behaviour.
Der Puls
- Eight months after the rollout began, some GP surgeries in England are still refusing or failing to prescribe weight-loss injections.
- Ministers admit the gap exists, and a fresh £25 million package is being pushed through a new GP contract to win over reluctant practices.
- Behind the hesitation lies a fear of workload: modelling suggested mass uptake could consume nearly a fifth of GP appointments.
- Eligible patients who qualify under strict criteria are still struggling to obtain the drug, while around 2.4 million people already buy it privately.
- The outcome now hangs on whether the incentives close the access gap and calm the workload anxieties before the fairness divide widens further.
Eight months into the NHS's mass rollout of weight-loss injections, the health system in England is still finding its footing: some family doctors have not yet begun prescribing, and the government has answered with a £25 million incentive. It is a familiar human tension, the wish to offer a new remedy fairly to everyone who needs it, set against the practical limits of the clinicians who must deliver it. Whether money can bridge that distance between a promise made at the top and the consulting room where it is kept remains an open question.
Eight months after the NHS began offering weight-loss injections on a mass scale, the programme has a visible hole in it. Some GP surgeries in England are still not prescribing the drugs, and the Department of Health and Social Care has acknowledged as much. The start was cautious by design, with strict rules limiting treatment to people who are severely obese and carry other serious health conditions.
The government's response is to offer money. A £25 million package, part of a new GP contract, aims to reward family doctors who prescribe and who refer eligible patients to specialist weight management services. Behind the hesitation sits a older worry: when the rollout was planned, leading GPs warned that demand could swamp their already stretched workloads.
Meanwhile, those who can pay have not waited. Around 2.4 million people in the UK take weight-loss drugs, mostly privately, and research suggests women and the better-off dominate that private market. Health Secretary Wes Streeting argues that access should follow need rather than ability to pay, and he warns of rogue prescribers selling dangerous unlicensed versions.
Whether £25 million is enough to move reluctant practices, and whether it eases the workload fears behind their caution, is the question now being watched.
Eight months after the NHS began rolling out weight-loss injections on a mass scale, some GP surgeries in England still are not prescribing them. The Department of Health and Social Care has acknowledged as much, confirming that not all practices prescribe the drugs. That admission points to a real gap in a programme that started last summer under strict eligibility rules.
The government's answer, announced as part of a new GP contract, is money. A £25 million package of financial incentives is meant to encourage family doctors to prescribe the medications and to refer eligible patients to dedicated weight management services. The aim is to narrow the differences in access that exist across the country.
The worry that shadowed the launch was workload. When the initiative began, leading GPs warned that the new prescriptions could add significantly to their burden. NHS England had previously modelled what would happen if all eligible patients, thought to number over three million, came forward in the first year. If 70 per cent of them were started on treatment, the effect on general practice would be profound, taking up 18 per cent of GP appointments.
The rollout is deliberately slow. NHS England has set out a phased introduction of Mounjaro over up to 12 years, with some 220,000 patients prioritised in the first three. The once-weekly injection is initially limited to people who are severely obese and who also have a range of other health problems. Even so, current data suggests that patients who meet those criteria now cannot always get the drug.
Meanwhile, the private market has moved faster. An estimated 2.4 million people in the UK are taking weight-loss drugs, and most of them obtain treatment privately. Research published earlier this month suggests that women and the middle classes dominate take-up of private prescriptions for the injections.
Health and Social Care Secretary Wes Streeting framed the incentives as a matter of fairness. He said weight-loss drugs can be a real game changer for those who need them, and that he is determined access should be based on need, not ability to pay. He pointed to people who can spare the cash buying privately, and to the spread of rogue prescribers selling dangerous unlicensed drugs that put patients at risk.
Streeting described the incentives as one part of a wider public health package to ease the £11 billion burden that obesity places on the health service and the economy. He said they would bring the principle of fairness, which he said has always underpinned the NHS, to obesity jabs, with the phased rollout reaching those with the highest clinical need first.
What to watch is whether £25 million is enough to persuade reluctant practices, and whether it eases the workload fears that made some GPs hesitant in the first place.
Bemerkenswerte Zitate
Weight-loss drugs can be a real game changer for those who need them, and access should be based on need, not ability to pay.— Wes Streeting, Health and Social Care Secretary
Möchten Sie die ganze Geschichte?
Das Original lesen bei The Independent ↗
Politics & Governance